Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Sees Significant Decrease in Short Interest

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totaling 528 shares, a drop of 15.1% from the March 15th total of 622 shares. Based on an average daily trading volume, of 742 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.3% of the shares of the stock are short sold.

Amplify Weight Loss Drug & Treatment ETF Stock Up 0.7%

Shares of THNR stock opened at $25.05 on Friday. Amplify Weight Loss Drug & Treatment ETF has a fifty-two week low of $19.97 and a fifty-two week high of $27.28. The stock has a market capitalization of $4.26 million, a P/E ratio of 24.31 and a beta of 0.58. The stock has a 50-day simple moving average of $25.07 and a 200 day simple moving average of $25.05.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently bought a new position in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC purchased a new stake in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF as of its most recent SEC filing.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.